Stephen obtained his PhD in Molecular Biology at Imperial College, London, before moving on to postdoctoral positions in Australia.
He first identified the genes required for development of the Drosophila brain and then generated one of the first mouse models of cystic fibrosis with the same mutation as found in humans. This was followed by work on gene therapy for cystic fibrosis in a collaboration between Boehringer Ingelheim and the Medical Research Council (MRC) Human Genetics Unit in Edinburgh.
Stephen joined AstraZeneca as a Team Leader in 1997 and has provided support for many drug discovery projects around target identification, validation and reagent generation. He has also been a project leader for several small molecule and biologics project teams. In 2002, he became a Principal Scientist and in 2011 moved to Gothenburg, as part of the formation of the iMed for Respiratory and Inflammation and Autoimmunity unit within the IMED Biotech Unit. Since moving to Gothenburg, he has led teams carrying out target validation and biomarker discovery.
New approaches to the treatment of asthma
CLINICAL TRIALS NCT01560234 (SAD) AND NCT01818869 (MAD)
Member of project team that delivered first ever data on safety and tolerability of an inhaled TLR7 agonist
LEADING 10 NEW DRUG PROJECTS
Leading a team that delivered 10 new drug projects into the AstraZeneca portfolio
ONE OF THE FIRST TO GENERATE MICE CARRYING A HUMAN CYSTIC FIBROSIS MUTATION
Cystic fibrosis mice carrying the missense mutation G551D replicate human genotype-phenotype correlations. EMBO.J, 15, 955-963
G551D cystic fibrosis mice exhibit abnormal regulation of inflammation in lungs and macrophages
Thomas GR, Costelloe EA, Lunn DP, Stacey KJ, Delaney SJ, Passey R, McGlinn EC, McMorran BJ, Ahadizadeh A, Geczy CL, Wainwright BJ, Hume DA. jimmunol 2000: 164.7.3870
Rapid simultaneous clong of drug targets from multiple mammalian species
Jupp R1, Dusanjh PK, Walding A, McHale M, Belfield GP, Delaney SJ. 2006 Jun;34(3):295-303.
I’m excited by working on the TLR-like receptors because through our experience and great collaborators we’re able to make real progress in a difficult area.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.